Biogen has been an ‘uninvestable’ stock for awhile, says Mizuho’s Jared Holz

June 14, 2023

Jared Holz, Mizuho Securities healthcare sector specialist, joins ‘Fast Money’ to talk controversy brewing at Biogen, Alzheimer’s drug approval roadblocks in Europe, and more.

Mizuho news from around the globe
Mizuho Global News
Back to top